261 related articles for article (PubMed ID: 19197326)
1. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients.
Victora GD; Socorro-Silva A; Volsi EC; Abdallah K; Lima FD; Smith RB; Moyses RA; Zárate-Bladés CR; Michaluart P; Silva CL; Kalil J; Coelho V
Cancer Gene Ther; 2009 Jul; 16(7):598-608. PubMed ID: 19197326
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck.
Michaluart P; Abdallah KA; Lima FD; Smith R; Moysés RA; Coelho V; Victora GD; Socorro-Silva A; Volsi EC; Zárate-Bladés CR; Ferraz AR; Barreto AK; Chammas MC; Gomes R; Gebrim E; Arakawa-Sugueno L; Fernandes KP; Lotufo PA; Cardoso MR; Kalil J; Silva CL
Cancer Gene Ther; 2008 Oct; 15(10):676-84. PubMed ID: 18535616
[TBL] [Abstract][Full Text] [Related]
3. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck.
Gleich LL; Gluckman JL; Nemunaitis J; Suen JY; Hanna E; Wolf GT; Coltrera MD; Villaret DB; Wagman L; Castro D; Gapany M; Carroll W; Gillespie D; Selk LM
Arch Otolaryngol Head Neck Surg; 2001 Jul; 127(7):775-9. PubMed ID: 11448348
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene.
Changhong S; Hai Z; Limei W; Jiaze A; Li X; Tingfen Z; Zhikai X; Yong Z
Tuberculosis (Edinb); 2009 Jan; 89(1):54-61. PubMed ID: 19056317
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of adjuvant-induced arthritis by DNA vaccination with the 70-kd or the 90-kd human heat-shock protein: immune cross-regulation with the 60-kd heat-shock protein.
Quintana FJ; Carmi P; Mor F; Cohen IR
Arthritis Rheum; 2004 Nov; 50(11):3712-20. PubMed ID: 15529360
[TBL] [Abstract][Full Text] [Related]
7. Strong humoral response elicited by a DNA vaccine targeting gastrin-releasing peptide with optimized adjuvants inhibits murine prostate carcinoma growth in vivo.
Lu Y; Mekoo DJ; Ouyang K; Hu X; Liu Y; Lin M; Jin L; Cao R; Li T; Zhang Y; Fan H; Liu J
Endocr Relat Cancer; 2009 Dec; 16(4):1171-84. PubMed ID: 19648182
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).
Johnson LE; Frye TP; Arnot AR; Marquette C; Couture LA; Gendron-Fitzpatrick A; McNeel DG
Vaccine; 2006 Jan; 24(3):293-303. PubMed ID: 16115700
[TBL] [Abstract][Full Text] [Related]
9. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells.
Karcher J; Dyckhoff G; Beckhove P; Reisser C; Brysch M; Ziouta Y; Helmke BH; Weidauer H; Schirrmacher V; Herold-Mende C
Cancer Res; 2004 Nov; 64(21):8057-61. PubMed ID: 15520216
[TBL] [Abstract][Full Text] [Related]
10. Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65.
Yi H; Rong Y; Yankai Z; Wentao L; Hongxia Z; Jie W; Rongyue C; Taiming L; Jingjing L
Vaccine; 2006 Mar; 24(14):2575-84. PubMed ID: 16420967
[TBL] [Abstract][Full Text] [Related]
11. Xenovaccinotherapy for colorectal cancer.
Seledtsov VI; Niza NA; Felde MA; Shishkov AA; Samarin DM; Seledtsova GV; Seledtsov DV
Biomed Pharmacother; 2007; 61(2-3):125-30. PubMed ID: 17258887
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients.
Conry RM; Curiel DT; Strong TV; Moore SE; Allen KO; Barlow DL; Shaw DR; LoBuglio AF
Clin Cancer Res; 2002 Sep; 8(9):2782-7. PubMed ID: 12231517
[TBL] [Abstract][Full Text] [Related]
13. Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope.
Lu Y; Ouyang K; Fang J; Zhang H; Wu G; Ma Y; Zhang Y; Hu X; Jin L; Cao R; Fan H; Li T; Liu J
Vaccine; 2009 Aug; 27(39):5411-8. PubMed ID: 19616501
[TBL] [Abstract][Full Text] [Related]
14. Pathogenic role of tonsillar lymphocytes in associated with HSP60/65 in Pustulosis palmaris et plantaris.
Hayashi M; Fujihara K; Beder LB; Yamamoto Y; Hotomi M; Yamanaka N
Auris Nasus Larynx; 2009 Oct; 36(5):578-85. PubMed ID: 19268507
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
[TBL] [Abstract][Full Text] [Related]
17. A clinical trial of active immunotherapy with anti-idiotypic vaccine in nasopharyngeal carcinoma patients.
Li G; Xie L; Zhou G; Fu H; Zhou J; Sun Q
Chin Med J (Engl); 2002 Apr; 115(4):567-70. PubMed ID: 12133300
[TBL] [Abstract][Full Text] [Related]
18. Effect of hsp65 DNA vaccination carrying immunostimulatory DNA sequences (CpG motifs) against Mycobacterium leprae multiplication in mice.
Nomaguchi H; Mukai T; Takeshita F; Matsuoka M; Maeda Y; Aye TM; Jahan N; Yogi Y; Endo M; Sato Y
Int J Lepr Other Mycobact Dis; 2002 Sep; 70(3):182-90. PubMed ID: 12483966
[TBL] [Abstract][Full Text] [Related]
19. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy: a new alternative treatment for head and neck squamous cell carcinoma].
Bron L; Romero P
Bull Cancer; 2007 Sep; 94(9):793-7. PubMed ID: 17878099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
